Drug Development Consulting
Holistic scientific advice at each stage of drug development
Our Holistic Approach
Our Drug Development Consultants work with you to design and implement successful drug development programs. With industry leading scientific expertise across a range of technical disciplines, we help customers across all stages of development, from candidate selection to commercial launch.
Our consultants have a proven track-record of cutting across industry silos to reduce the time and cost of development. With hands-on development experience across hundreds of drug molecules and product types, we’ll help you avoid critical pitfalls, manage risks and maximise the potential for success.
Our team of drug development consultants
-
Dr. Vanessa Zann
Senior Drug Development Consultant
Thank you for getting in touch with us.
We will send you a reply in the next 48 hours.
If you have not heard from us in the next 48 hours, do not hesitate to call us on:
UK +44 (0)115 974 9000 / US +1-800-769-3518
Ask questions to our scientific team
Leveraging decades of drug development experience
What our consultants do
-
Assess each molecule holistically to understand the complex interplay between drug substance, drug product and clinical performance
-
Listen to customers, understand goals, interpret data & guide development
-
Integrate multiple-development services and build robust development plans
Customer Benefits
-
Our consultants pre-emptively identify scientific challenges and mitigate development risks
-
Our consultants design drug development strategies that are right first time and eliminating delays
-
Our consultants streamline outsourcing, eliminate costly and time-consuming tech transfers and provides consistent scientific direction
Consultancy by stage of development
Candidate Selection - Selecting the right molecules for development
Early Development - Accelerating molecules through to proof-of-concept
Late Development - Accelerating products through to commercial manufacture
From solubility enhancement to complex oral solid dose, from pediatric dosage forms to and injectables, let our experts help you move from discovery into development, from first-in-human to proof-of-concept, and through to late phase and commercial manufacturing.
Resources
Access our resources
-
Case StudiesDCS classification of NCE - Case studyUS Biotech wanted to determine the DCS (Developability Classification System) designation for their small molecule. This included project scope and outcomes of the project.
-
WhitepaperThe First Kilograms of GMP Drug SubstanceAt Quotient Sciences, a core component of our integrated offering is our capability in drug substance process research, development, and manufacturing, carried out at our state-of-the-art facility in Alnwick, UK. Read our latest white paper on our drug substance capabilities.
-
ArticleConference Report from the European Bioanalysis Forum Workshop: toward harmonized implementation of the ICH M10 guidelineIn this report, the European Bioanalysis Forum shares the proposals for harmonized implementation of the ICH M10 guideline on bioanalytical method validation and study sample analysis from the ICH M10 workshop.
-
WhitepaperSynthesis to Clinic: A streamlined approach to 14C human ADME studiesWith over 30 years of experience, Quotient Sciences is a leading provider of 14C-enabled drug development programs, having successfully conducted over 350 human ADME and other radiolabeled programs to date. Learn how our Synthesis-to-Clinic® offering incorporates radiosynthesis of the 14C-labeled drug substance through all required steps of the human study and the final clinical report in a single, integrated program of work.